Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem

Respiratory Syncytial Virus Infects Regulatory B Cells in Human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity

(2017) Dania Zhivaki et al.   IMMUNITY

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

(2017) Judith Falloon et al.   JOURNAL OF INFECTIOUS DISEASES

Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells

(2017) B. Cortjens et al.   JOURNAL OF VIROLOGY

Universal vaccine against respiratory syncytial virus A and B subtypes

(2017) Jeong-Yoon Lee et al.   PLoS One

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

(2017) Qing Zhu et al.   Science Translational Medicine

Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25–26 April 2016

(2017) Birgitte K. Giersing et al.   VACCINE

Animal models of respiratory syncytial virus infection

(2017) Geraldine Taylor   VACCINE

Ongoing developments in RSV prophylaxis: a clinician’s analysis

(2017) Fariba Rezaee et al.   Current Opinion in Virology

Respiratory syncytial virus: prospects for new and emerging therapeutics

(2017) Patricia A. Jorquera et al.   Expert Review of Respiratory Medicine

Preclinical evaluation of bacterially produced RSV-G protein vaccine: Strong protection against RSV challenge in cotton rat model

(2017) Sandra Fuentes et al.   Scientific Reports

ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients

(2016) Jens Gottlieb et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation

(2016) Christopher C. Stobart et al.   Nature Communications

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

(2015) Laurent Detalle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials

(2015) Lindsay Broadbent et al.   Influenza and Other Respiratory Viruses

CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells

(2015) Tatiana Chirkova et al.   JOURNAL OF GENERAL VIROLOGY

Respiratory Syncytial Virus Attachment Glycoprotein Contribution to Infection Depends on the Specific Fusion Protein

(2015) Jia Meng et al.   JOURNAL OF VIROLOGY

Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium

(2015) Rémi Villenave et al.   JOURNAL OF VIROLOGY

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial

(2015) Katherine L O'Brien et al.   LANCET INFECTIOUS DISEASES

An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice

(2015) Seyhan Boyoglu-Barnum et al.   VIROLOGY

Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures

(2015) Sara M. Johnson et al.   PLoS Pathogens

CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner

(2015) Kwang-Il Jeong et al.   PLoS One

Effects of Anti-G and Anti-F Antibodies on Airway Function after Respiratory Syncytial Virus Infection

(2014) Junyan Han et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Within-Host Whole-Genome Deep Sequencing and Diversity Analysis of Human Respiratory Syncytial Virus Infection Reveals Dynamics of Genomic Diversity in the Absence and Presence of Immune Pressure

(2014) Y. H. Grad et al.   JOURNAL OF VIROLOGY

Limited Type I Interferons and Plasmacytoid Dendritic Cells during Neonatal Respiratory Syncytial Virus Infection Permit Immunopathogenesis upon Reinfection

(2014) S. A. Cormier et al.   JOURNAL OF VIROLOGY

Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

(2014)   PEDIATRICS

Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein

(2014) John T. Bates et al.   VIROLOGY

Immunity to RSV in Early-Life

(2014) Laura Lambert et al.   Frontiers in Immunology

Respiratory Syncytial Virus G Protein CX3C Motif Impairs Human Airway Epithelial and Immune Cell Responses

(2013) T. Chirkova et al.   JOURNAL OF VIROLOGY

A Respiratory Syncytial Virus (RSV) Anti-G Protein F(ab')2 Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-Infected BALB/c Mice

(2013) S. Boyoglu-Barnum et al.   JOURNAL OF VIROLOGY

RSV Immunoprophylaxis: Does the Benefit Justify the Cost?

(2013) H. C. Meissner et al.   PEDIATRICS

Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein

(2013) Zhiwu Sun et al.   Viruses-Basel

Development of asthma is determined by the age-dependent host response to respiratory virus infection: therapeutic implications

(2012) Erwin W Gelfand   CURRENT OPINION IN IMMUNOLOGY

The Secreted G Protein of Human Respiratory Syncytial Virus Antagonizes Antibody-Mediated Restriction of Replication Involving Macrophages and Complement

(2012) A. Bukreyev et al.   JOURNAL OF VIROLOGY

Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma

(2012) Nandini Krishnamoorthy et al.   NATURE MEDICINE

Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab

(2011) Qing Zhu et al.   JOURNAL OF INFECTIOUS DISEASES

Palivizumab‐Resistant Human Respiratory Syncytial Virus Infection in Infancy

(2010) Ortwin Adams et al.   CLINICAL INFECTIOUS DISEASES

Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

(2009) Mohammad Tabrizi et al.   AAPS Journal

Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients

(2009) E. J. Collarini et al.   JOURNAL OF IMMUNOLOGY

Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice

(2009) Lia M. Haynes et al.   JOURNAL OF INFECTIOUS DISEASES

Respiratory Syncytial Virus Proteins Modulate Suppressors of Cytokine Signaling 1 and 3 and the Type I Interferon Response to Infection by a Toll-Like Receptor Pathway

(2009) Christine M. Oshansky et al.   VIRAL IMMUNOLOGY